Literature DB >> 33452433

Prediction of short-term antidepressant response using probabilistic graphical models with replication across multiple drugs and treatment settings.

Arjun P Athreya1, Tanja Brückl2, Elisabeth B Binder2, A John Rush3,4,5, Joanna Biernacka6, Mark A Frye7, Drew Neavin8, Michelle Skime7, Ditlev Monrad9, Ravishankar K Iyer10, Taryn Mayes11, Madhukar Trivedi11, Rickey E Carter12, Liewei Wang1, Richard M Weinshilboum1, Paul E Croarkin7, William V Bobo13.   

Abstract

Heterogeneity in the clinical presentation of major depressive disorder and response to antidepressants limits clinicians' ability to accurately predict a specific patient's eventual response to therapy. Validated depressive symptom profiles may be an important tool for identifying poor outcomes early in the course of treatment. To derive these symptom profiles, we first examined data from 947 depressed subjects treated with selective serotonin reuptake inhibitors (SSRIs) to delineate the heterogeneity of antidepressant response using probabilistic graphical models (PGMs). We then used unsupervised machine learning to identify specific depressive symptoms and thresholds of improvement that were predictive of antidepressant response by 4 weeks for a patient to achieve remission, response, or nonresponse by 8 weeks. Four depressive symptoms (depressed mood, guilt feelings and delusion, work and activities and psychic anxiety) and specific thresholds of change in each at 4 weeks predicted eventual outcome at 8 weeks to SSRI therapy with an average accuracy of 77% (p = 5.5E-08). The same four symptoms and prognostic thresholds derived from patients treated with SSRIs correctly predicted outcomes in 72% (p = 1.25E-05) of 1996 patients treated with other antidepressants in both inpatient and outpatient settings in independent publicly-available datasets. These predictive accuracies were higher than the accuracy of 53% for predicting SSRI response achieved using approaches that (i) incorporated only baseline clinical and sociodemographic factors, or (ii) used 4-week nonresponse status to predict likely outcomes at 8 weeks. The present findings suggest that PGMs providing interpretable predictions have the potential to enhance clinical treatment of depression and reduce the time burden associated with trials of ineffective antidepressants. Prospective trials examining this approach are forthcoming.

Entities:  

Year:  2021        PMID: 33452433     DOI: 10.1038/s41386-020-00943-x

Source DB:  PubMed          Journal:  Neuropsychopharmacology        ISSN: 0893-133X            Impact factor:   7.853


  42 in total

1.  Measurement-Based Care Versus Standard Care for Major Depression: A Randomized Controlled Trial With Blind Raters.

Authors:  Tong Guo; Yu-Tao Xiang; Le Xiao; Chang-Qing Hu; Helen F K Chiu; Gabor S Ungvari; Christoph U Correll; Kelly Y C Lai; Lei Feng; Ying Geng; Yuan Feng; Gang Wang
Journal:  Am J Psychiatry       Date:  2015-08-28       Impact factor: 18.112

Review 2.  The integrative management of treatment-resistant depression: a comprehensive review and perspectives.

Authors:  Andre F Carvalho; Michael Berk; Thomas N Hyphantis; Roger S McIntyre
Journal:  Psychother Psychosom       Date:  2014-01-22       Impact factor: 17.659

3.  Early switch strategy in patients with major depressive disorder.

Authors:  Chi-Un Pae; Sheng-Min Wang; Seung-Yup Lee; Soo-Jung Lee
Journal:  Expert Rev Neurother       Date:  2012-10       Impact factor: 4.618

4.  Depression is not a consistent syndrome: An investigation of unique symptom patterns in the STAR*D study.

Authors:  Eiko I Fried; Randolph M Nesse
Journal:  J Affect Disord       Date:  2014-10-14       Impact factor: 4.839

5.  When should a trial of fluoxetine for major depression be declared failed?

Authors:  Frederic M Quitkin; Eva Petkova; Patrick J McGrath; Bonnie Taylor; Charles Beasley; Jonathan Stewart; Jay Amsterdam; Maurizio Fava; Jerrold Rosenbaum; Frederick Reimherr; Jan Fawcett; Ying Chen; Donald Klein
Journal:  Am J Psychiatry       Date:  2003-04       Impact factor: 18.112

Review 6.  Onset, time course and trajectories of improvement with antidepressants.

Authors:  Raymond W Lam
Journal:  Eur Neuropsychopharmacol       Date:  2012       Impact factor: 4.600

Review 7.  Early switching strategies in antidepressant non-responders: current evidence and future research directions.

Authors:  Paul A Kudlow; Roger S McIntyre; Raymond W Lam
Journal:  CNS Drugs       Date:  2014-07       Impact factor: 5.749

8.  Evaluating and monitoring treatment response in depression using measurement-based assessment and rating scales.

Authors:  Madhukar H Trivedi
Journal:  J Clin Psychiatry       Date:  2013-07       Impact factor: 4.384

9.  Scaling-up treatment of depression and anxiety: a global return on investment analysis.

Authors:  Dan Chisholm; Kim Sweeny; Peter Sheehan; Bruce Rasmussen; Filip Smit; Pim Cuijpers; Shekhar Saxena
Journal:  Lancet Psychiatry       Date:  2016-04-12       Impact factor: 27.083

Review 10.  Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis.

Authors:  Andrea Cipriani; Toshi A Furukawa; Georgia Salanti; Anna Chaimani; Lauren Z Atkinson; Yusuke Ogawa; Stefan Leucht; Henricus G Ruhe; Erick H Turner; Julian P T Higgins; Matthias Egger; Nozomi Takeshima; Yu Hayasaka; Hissei Imai; Kiyomi Shinohara; Aran Tajika; John P A Ioannidis; John R Geddes
Journal:  Lancet       Date:  2018-02-21       Impact factor: 79.321

View more
  5 in total

1.  Predicting treatment outcome in depression: an introduction into current concepts and challenges.

Authors:  Nicolas Rost; Elisabeth B Binder; Tanja M Brückl
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2022-05-19       Impact factor: 5.270

2.  Evidence for machine learning guided early prediction of acute outcomes in the treatment of depressed children and adolescents with antidepressants.

Authors:  Arjun P Athreya; Jennifer L Vande Voort; Julia Shekunov; Sandra J Rackley; Jarrod M Leffler; Alastair J McKean; Magdalena Romanowicz; Betsy D Kennard; Graham J Emslie; Taryn Mayes; Madhukar Trivedi; Liewei Wang; Richard M Weinshilboum; William V Bobo; Paul E Croarkin
Journal:  J Child Psychol Psychiatry       Date:  2022-03-15       Impact factor: 8.265

3.  Multi-omics driven predictions of response to acute phase combination antidepressant therapy: a machine learning approach with cross-trial replication.

Authors:  Jeremiah B Joyce; Caroline W Grant; Duan Liu; Siamak MahmoudianDehkordi; Rima Kaddurah-Daouk; Michelle Skime; Joanna Biernacka; Mark A Frye; Taryn Mayes; Thomas Carmody; Paul E Croarkin; Liewei Wang; Richard Weinshilboum; William V Bobo; Madhukar H Trivedi; Arjun P Athreya
Journal:  Transl Psychiatry       Date:  2021-10-07       Impact factor: 7.989

4.  Effectiveness of common antidepressants: a post market release study.

Authors:  Farrokh Alemi; Hua Min; Melanie Yousefi; Laura K Becker; Christopher A Hane; Vijay S Nori; Janusz Wojtusiak
Journal:  EClinicalMedicine       Date:  2021-10-25

Review 5.  Use of Mobile and Wearable Artificial Intelligence in Child and Adolescent Psychiatry: Scoping Review.

Authors:  Victoria Welch; Tom Joshua Wy; Anna Ligezka; Leslie C Hassett; Paul E Croarkin; Arjun P Athreya; Magdalena Romanowicz
Journal:  J Med Internet Res       Date:  2022-03-14       Impact factor: 7.076

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.